Rates of Invasive Pneumococcal Disease in Adults With HIV in the Era of 13-Valent Pneumococcal Conjugate Vaccine, 2008-2018

September 29 - October 3, 2021; Virtual
Active surveillance demonstrates that introduction of PCV13 led to declines in IPD in people with and without HIV and suggests benefits of newly approved higher valency PCVs.
Format: Microsoft PowerPoint (.ppt)
File Size: 419 KB
Released: October 7, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue